Lyell Immunopharma, Inc. Other Noncash Income (Expense)
Lyell Immunopharma, Inc. (LYEL) reported Other Noncash Income (Expense) of -$324.00 thousand for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2021-08-12
- 2021-06-30: Other Noncash Income (Expense) 6 month -$324.00K.
- 2020-06-30: Other Noncash Income (Expense) 6 month $0.00.
| Period end | Other Noncash Income (Expense) 6 month |
|---|---|
| 2021-06-30 | -$324.00K 10-Q · filed 2021-08-12 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |